Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Medicus Pharma (MDCX) announced hat members of its executive management team, led by Dr. Raza Bokhari, Executive Chairman & CEO, will participate in a live fireside chat on Thursday, March 19, 2026, hosted by Kumaraguru Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets. Dr. Bokhari will provide a company update including a review of the positive SkinJect SKNJCT-003 Phase 2 clinical trial topline results that were reported earlier this month. Key findings of the study include 73% clinical Clearance in the 200-microgram Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. The SKNJCT-003 Phase 2 study is a “randomized, double-blind, three-arm Phase 2 study evaluating two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control in patients with nodular basal cell carcinoma.